Crohn Disease (CD)
Conditions
Brief summary
From January 2020 to May 2025, 303 CD patients and 514 normal controls were retrospectively collected from Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Our study aimed to explore the the relationship of interleukin-7 receptor (IL-7R) gene polymorphisms with the risk of Crohn's disease (CD) onset, the clinicopathological features of CD and the efficacy of infliximab (IFX) therapy.
Detailed description
From January 2020 to May 2025, 303 CD patients and 514 normal controls were retrospectively collected from Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Our study aimed to explore the the relationship of interleukin-7 receptor (IL-7R) gene polymorphisms with the risk of Crohn's disease (CD) onset, the clinicopathological features of CD and the efficacy of infliximab (IFX) therapy. Multiple polymerase chain reaction ligase detection technology was used to detect the genotype of IL-7R (rs6897932, rs1494555, rs1494558). According to the Montreal CD classification criteria, patients were divided into different subgroups. The Crohn's Disease Activity Index (CDAI) is used to evaluate clinical activity, while the Simplified Crohn's Disease Endoscopic Score (SES-CD) is used to assess endoscopic activity.
Interventions
BIOLOGICALInfliximab
Intravenous injection of IFX (5mg/kg) at weeks 0, 2, and 6, followed by intravenous injection of the same dose of IFX every 8 weeks to maintain treatment.
Sponsors
Second Affiliated Hospital of Wenzhou Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* diagnosed CD based on comprehensive clinical, colonoscopy, histopathological, laboratory, and radiographic examination results
Exclusion criteria
* rheumatoid arthritis, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis, tumors, etc.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Genotypes of IL-7R | Baseline | multiplex polymerase chain reaction-ligase detection reaction technique |
Countries
China
Outcome results
None listed